Antagonism of adenosine receptors by caffeine and caffeine metabolites in equine forebrain tissues

American Journal of Veterinary Research

Volumn 64, Issue 2, 2003, Pages 216-224

  Chou, Chi Chung ^a,b   Vickroy, Thomas W ^a  

^a University of Florida College of Veterinary Medicine   (United States)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; BARBITURIC ACID DERIVATIVE; BEUTHANASIA; CAFFEINE; CENTRAL STIMULANT AGENT; DRUG METABOLITE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); METHYLXANTHINE DERIVATIVE; NUCLEOTIDE; PARAXANTHINE; RADIOLIGAND; RECEPTOR SUBTYPE; SULFUR 35; THEOBROMINE; THEOPHYLLINE; TRITIUM;

ANIMAL TISSUE; ARTICLE; AUTOPSY; BINDING ASSAY; BRAIN CORTEX; BRAIN HOMOGENATE; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BINDING SITE; DRUG RECEPTOR BINDING; FOREBRAIN; HORSE; MALE; NONHUMAN; PROTEIN INTERACTION; RADIOASSAY; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SPECIES COMPARISON;

ANIMALS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL CORTEX; HORSES; MALE; NEOSTRIATUM; PROSENCEPHALON; RECEPTORS, PURINERGIC P1; THEOBROMINE; THEOPHYLLINE;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0037317028     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2003.64.216     Document Type: Article

References (45)

1. Haywood PE, Teale P, Moss MS. The excretion of theobromine in Thoroughbred racehorses after feeding compounded cubes containing cocoa husk-establishment of a threshold value in horse urine. Equine Vet J 1990;22:244-246.
2. Graham TE, Rush JW, van Soeren MH. Caffeine and exercise: metabolism and performance. Can J App Physiol 1994;19: 111-138.
3. Nehlig A, Debry G. Caffeine and sports activity: a review. Int J Sports Med 1994;15:215-223.
4. Herrmann-Frank A, Luttgau HC, Stephenson DG. Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story. J Muscle Res Cell Motil 1999;20:223-237.
5. Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 1992;17:139-170.
6. Daly JW. Mechanism of action of caffeine. In: Garattini S, ed. Caffeine, coffee, and health. New York: Raven Press Ltd, 1993;97-150.
7. Howell LL. Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther 1993;266:894-903.
8. Guthrie JR, Mayler WG. Interaction between caffeine and adenosine on calcium exchangeability in mammalian atria. Arch Int Pharmacodyn Ther 1967;170:249-255.
9. Weiss B, Hait WN. Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents. Annu Rev Pharmacol Toxicol 1977;17:441-477.
10. Wachtel H. Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′, 5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology (Berl) 1982;77:309-316.
11. Fredholm BB. Astra award lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 1995;76: 93-101.
12. Fredholm BB, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994;46:143-156.
13. Schwabe U, Ukena D, Lohse MJ. Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1985;330:212-221.
14. Ukena D, Jacobson KA, Padgett WL, et al. Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett 1986;209:122-127.
15. Maemoto T, Finlayson K, Olverman H, et al. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and phrazologyridine based antagonists. Br J Pharmacol 1997;122:1202-1208.
16. 35S]thio)triphosphate binding. Mol Pharmacol 1993;44:115-123.
17. Cheng Y, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
18. Fleming WW, Westfall DP, Lande S, et al. Log-normal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J Pharmacol Exp Ther 1972;181:339-345.
19. Poucher SM, Keddie JR, Singh P, et al. The in vitro pharmacology of ZM 241385, a potent, non-xanthine, A2a selective adenosine receptor antagonist. Br J Pharmacol 1995;115:1096-1102.
20. Keddie JR, Poucher SM, Shaw GR, et al. In vivo characterization of ZM 241385, a selective adenosine A2A receptor antagonist. Eur J Pharmacol 1996;301:107-113.
21. Ongini E, Dionisotti S, Gessi S, et al. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999; 359:7-10.
22. 3H]-ZM241385, an antagonist radioligand for adenosine A2a receptors in rat brain. Eur J Pharmacol 2001;411:205-210.
23. 35S]guanosine5′-(gamma-thio)triphosphate autoradiography. Neuroscience 1999;90:1265-1279.
24. 35S] GTPgammaS binding in brain modulation by endogenous adenosine. Neuropharmacol 2000;39:282-289.
25. Bruns RF, Fergus JH, Badger EW, et al. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1, 3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol 1987;335:59-63.
26. Lohse MJ, Klotz KN, Lindenborn-Fotinos J, et al. 8-cyclopentyl-1, 3-dipropylxanthine (DPCPX)-a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1987;336:204-210.
27. Klotz KN, Vogt H, Hoda TS. Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labeling. Naunyn Schmiedebergs Arch Pharmacol 1991;343:196-201.
28. 3H] CGS 21680 to human and rat brain: evidence for multiple affinity sites. J Neurochem. 1990;55:1763-1771.
29. Weaver DR. A2a adenosine receptor gene expression in developing rat brain. Mol Brain Res 1993;20:313-327.
30. Lopes LV, Cunha RA, Ribeiro JA. Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A2A receptors in the limbic cortex, but not striatum, of aged rats. J Neurochem 1999;73:1733-1738.
31. 3H]N-6-phenylisopropyladenosine. Naunyn Schmiedebergs Arch Pharmacol 1980;313:179-187.
32. 3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther 1989;251:888-893.
33. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998;50:413-492.
34. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Ann Rev Neurosci 2001;24: 31-55.
35. Van Calker D, Muller M, Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 1979;33:999-1005.
36. Daly JW, Butts-Lamb P, Padgett W. Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol 1983;3:69-80.
37. Kim YC, Ji XD, Jacobson KA. Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem 1996;39:4142-4148.
38. Phillis JW, Goshgarian HG. Adenosine and neurotrauma: therapeutic perspectives. Neurol Res 2001;23:183-189.
39. Haas HL, Selbach O. Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 2000;362:375-381.
40. Edwards FA, Robertson SJ. The function of A2 adenosine receptors in the mammalian brain: evidence for inhibition vs. enhancement of voltage gated calcium channels and neurotransmitter release. Prog Brain Res 1999;120:265-273.
41. El Yacoubi M, Ledent C, Menard JF, et al. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br J Pharmacol 2000;129:1465-1473.
42. Kase H. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci Biotechnol Biochem 2001;65:1447-1457.
43. Fuxe K, Stromberg I, Popoli P, et al. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv Neurol 2001;86:345-353.
44. Greene EW, Woods WE, Tobin T. Pharmacology, pharmacokinetics, and behavioral effects of caffeine in horses. Am J Vet Res 1983;44:57-63.
45. Queiroz-Neto A, Zamur G, Carregaro AB, et al. Effects of caffeine on locomotor activity of horses: determination of the no-effect threshold. J Appl Toxicol 2001;21:229-234.